Better Therapeutics, Inc. (NASDAQ:BTTX) is up nearly 40% in premarket trading this morning. While it’s still just in the $1.25 range, so it’s well below most fund’s low price threshold, this is one that risk inclined investors should keep an eye on.
Better Therapeutics’ insiders, from officers to directors, have reportedly purchased over 12 million shares to zero sales over the past 12 months (https://www.nasdaq.com/market-activity/stocks/bttx/insider-activity). Better Therapeutics insiders now own more than half of the company and, if the $10 buys are any indication, BTTX could have significant upside potential.
